Benefit of Cusp overlap method for self‐expanding transcatheter aortic valves

The need for permanent pacemaker implantation (PPM) continues to be one of the main challenges in TAVR, especially with self-expanding valves, with a pacemaker implantation rate that varies between 17.5% and 30% in large randomized studies, vs. 4% to 6.5% with self-expanding valves. Therefore, in an attempt to prevent the need for PPM implantation, the<a href="https://solaci.org/en/2024/02/02/benefit-of-cusp-overlap-method-for-self%e2%80%90expanding-transcatheter-aortic-valves/" title="Read more" >...</a>

Use of Apixaban and Post TAVR Valve Thrombosis

TAVR can be associated to early valve thrombosis, characterized by thrombi formation near or attached to the prosthetic valve, with or without valve dysfunction. This dysfunction is associated with increased leaf thickening and reduced leaflet motion, as well as reduced orifice area or increased transvalvular gradient. Triggered multislice CT allows dynamic valve assessment and thrombosis<a href="https://solaci.org/en/2024/01/25/use-of-apixaban-and-post-tavr-valve-thrombosis/" title="Read more" >...</a>

TricValve: 12-Month Evolution

Tricuspid regurgitation has become increasingly common, and current pharmacological treatment options are limited. In turn, surgery, which is a complex alternative, carries considerable rates of complications and mortality. In response to this issue, various percutaneous systems are being developed, such as edge-to-edge treatment, percutaneous annuloplasty, and caval valve implantation (CAVI), among others. In the analysis<a href="https://solaci.org/en/2024/01/18/tricvalve-12-month-evolution/" title="Read more" >...</a>

¿Son las válvulas autoexpandibles una opción válida en las bicúspides?

Evolution of Bicuspid Valves at 12 Months

Severe aortic stenosis due to a bicuspid aortic valve (BAV) is uncommon, especially in individuals under 65 years of age. While there are usually no significant differences according to the type of valve when it comes to surgery, with transcatheter aortic valve replacement (TAVR) some may arise.  TAVR has seen significant advancements in the treatment<a href="https://solaci.org/en/2024/01/12/evolution-of-bicuspid-valves-at-12-months/" title="Read more" >...</a>

Luz roja para el TAVI en pacientes de bajo riesgo

MYVAL, a TAVR Balloon-Expandable Valve with Promising Results

TAVR has been shown beneficial over time, and with the development of new generation of prosthetic valves and implantation techniques, outcomes have been improved, reducing the incidence of leaks y and the need for definite pacemaker.  This study looked at the evolution of 100 patients with symptomatic aortic stenosis treated with Myval THV from Meril<a href="https://solaci.org/en/2023/12/19/myval-a-tavr-balloon-expandable-valve-with-promising-results/" title="Read more" >...</a>

¿Es frecuente el uso de IVUS para guiar la ATC?

Can Ultrasound Treat Aortic Stenosis?

Severe calcified aortic stenosis is a common condition that can currently be effectively treated with SAVR or TAVR. However, some patients, given comorbidities or anatomical characteristics, are not good candidates for these therapeutic alternatives.  The non-invasive ultrasound therapy (NIUT) has surged as viable alternative. It claims ultrasound might act on calcified valves, and mobilize tissue<a href="https://solaci.org/en/2023/12/05/can-ultrasound-treat-aortic-stenosis/" title="Read more" >...</a>

Debemos tener en cuenta a la isquemia crítica de MM II en el TAVI

Low Gradient, Normal Flow Aortic Stenosis: Changes in Quality of Life with TAVR

There is no question as regards the recommended treatment for symptomatic severe aortic stenosis, seeing as both transcatheter and surgical aortic valve replacement (TAVR and SAVR) have shown to significantly improve prognosis. This is despite the fact that there is still certain ambiguity around its characterization, which looks to define it according to hemodynamic severity<a href="https://solaci.org/en/2023/11/30/low-gradient-normal-flow-aortic-stenosis-changes-in-quality-of-life-with-tavr/" title="Read more" >...</a>

TCT 2023 | VIVA Trial: TAVR vs. SAVR in Patients with Severe Aortic Stenosis and Small Aortic Annulus

Degenerative aortic stenosis (AS) is the most common valve condition. A significant number of AS patients presents a small aortic annulus (SAA), especially women. Treating this group of patients remains challenging, seeing as they have a high incidence of suboptimal hemodynamic results.  Despite the development of TAVR (transcatheter aortic valve replacement), the current guidelines do<a href="https://solaci.org/en/2023/10/31/tct-2023-viva-trial-tavr-vs-savr-in-patients-with-severe-aortic-stenosis-and-small-aortic-annulus/" title="Read more" >...</a>

Anillos aórticos pequeños, ¿Qué válvula deberíamos elegir?

TAVI-in-TAVI with Balloon-Expandable Valves

TAVI (Transcatheter Aortic Valve Implantation) has proven to be beneficial and is currently performed in increasingly younger and lower-risk patients. However, as with surgical bioprostheses, structural deterioration, whether due to stenosis or regurgitation, is one of the challenges we must address.  While currently uncommon, this is an issue we will probably see more and more<a href="https://solaci.org/en/2023/09/12/tavi-in-tavi-with-balloon-expandable-valves/" title="Read more" >...</a>

Predictors and Evolution of Permanent Pacemaker After TAVR with Self-Expanding Valves

Transcatheter aortic valve replacement (TAVR) has shown remarkable benefits and continues to advance towards lower-risk patients and younger ages. However, one of its limitations lies in the demand for a permanent pacemaker (PPM), which during TAVR early stages with self-expanding valves reached 30%. Uncertainty persists regarding the evolution of patients undergoing PPM implantation after TAVR,<a href="https://solaci.org/en/2023/08/17/predictors-and-evolution-of-permanent-pacemaker-after-tavr-with-self-expanding-valves/" title="Read more" >...</a>